Smallpox and vaccinia

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 718-745

  Kennedy, Richard B ^a   Lane, J Michael ^b   Henderson, Donald A ^c   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902072152     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00010-0     Document Type: Chapter

References (461)

1. World Health Organization, Global Commission for the Certification of Smallpox Eradication The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication, Geneva, December 1979 1980, World Health Organization, Geneva, Switzerland.
2. Alcami A., Damon I., Evans D., et al. WHO Global Alert and Response: Scientific Review of Variola Virus Research, 1999-2010 2010, World Health Organization, Geneva, Switzerland.
3. Jenner E. An Inquiry into the Causes and Effects of the Variolae Vaccinae: A Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name Cow Pox 1978, Classics of Medicine Library, Birmingham, AL.
4. Kennedy R.B., Ovsyannikova I.G., Jacobson R.M., et al. The immunology of smallpox vaccines. Curr Opin Immunol 2009, 21:314-320.
5. Poland G.A., Grabenstein J.D., Neff J.M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005, 23:2078-2081.
6. Neff J., Modlin J., Birkhead G.S., et al. Monitoring the safety of a smallpox vaccination program in the United States: report of the Joint Smallpox Vaccine Safety Working Group of the Advisory Committee on Immunization Practices and the Armed Forces Epidemiological Board. Clin Infect Dis 2008, 46(suppl 3):S258-S270.
7. Frey S.E., Newman F.K., Kennedy J.S., et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 2009, 27:1637-1644.
8. McFadden G. Killing a killer: what next for smallpox?. PLoS Pathog 2010, 6:e1000727. 10.1371/journal.ppat.1000727.
9. Poland G.A., Lane J.M. Why not destroy the remaining smallpox virus stocks?. Vaccine 2011, 29:2823-2824.
10. Henderson D.A. Smallpox virus destruction and the implications of a new vaccine. Biosecur Bioterror 2011, 9:163-168.
11. World Health Organization, Global Commission for the Certification of Smallpox Eradication The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication, Geneva, December 1979 1980, World Health Organization, Geneva, Switzerland.
12. Ailbek K., Handelman S. Biohazard 1999, Random House, New York, NY.
13. Kennedy R.B., Ovsyannikova I., Poland G.A. Smallpox vaccines for biodefense. Vaccine 2009, 27(suppl 4):D73-D79.
14. Meseda C.A., Weir J.P. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox. Future Microbiol 2010, 5:1367-1382.
15. Baker R.O., Bray M., Huggins J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 2003, 57:13-23.
16. Shchelkunov S.N., Shcherbakov D.N., Maksyutov R.A., et al. Species-specific identification of variola, monkeypox, cowpox, and vaccinia viruses by multiplex real-time PCR assay. J Virol Methods 2011, 175:163-169.
17. Mohamed M.R., Rahman M.M., Lanchbury J.S., et al. Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses. Proc Natl Acad Sci U S A 2009, 106:9045-9050.
18. Kurth A., Nitsche A. Detection of human-pathogenic poxviruses. Methods Mol Biol 2011, 665:257-278.
19. Alcami A., Damon I., Evans D., et al. WHO Global Alert and Response: Scientific Review of Variola Virus Research, 1999-2010 2010, World Health Organization, Geneva, Switzerland.
20. de Korte W.E. Amaas, or kaffir milk-pox. Lancet 1904, 1:1273-1276.
21. Chapin C.V. Variation in type of infectious disease as shown by the history of smallpox in the United States 1895-1912. J Infect Dis 1913, 13:171-196.
22. Fenner F., Henderson D.A., Arita I., et al. Smallpox and Its Eradication 1988, World Health Organization, Geneva, Switzerland.
23. McNeill W.H. Plagues and Peoples 1976, Anchor Press, Garden City, NY.
24. Ruffer M. Pathological note on the royal mummies of the Cairo Museum. Studies in the Paleopathology of Egypt 1921, 175-176. Chicago University Press, Chicago, IL. R.L. Moodie (Ed.).
25. Hopkins D.R. The Greatest Killer: Smallpox in History 2002, University of Chicago Press, Chicago, IL.
26. Rhazes (Abu Bakr Muhammad Ibn Zakariya al-Razi De Variolis et Morbillis Commentarius. Med Class 1939, 4:22-84.
27. Dixon C.W. Smallpox 1962, J & A Churchill, London, England.
28. Moore J.C. The History of the Smallpox 1815, Longman Hurst Rees Orme and Brown, London, England.
29. Creighton C.A. History of Epidemics in Britain 1965, Cass, London, England.
30. Holwell J.Z. An account of the manner of inoculating for the smallpox in the East Indies. With some observations on the practice and mode of treating that disease in those parts 1767, London, England.
31. Operation of inoculation of the smallpox as performed in Bengall from R. Coult to Dr. Oliver Coult. An Account of the Diseases of Bengall 1731.
32. Macgowan D.J. Report on the Health of Wenchow for the Half-Year Ended 31 March 1884. Imperial Maritime Customs Med Rep 1884, 27:9-18.
33. Needham J. China and the origins of immunology. East Hortz 1980, 19:6-12.
34. Miller G. Putting Lady Mary in her place: a discussion of historical causation. Bull Hist Med 1981, 55:2-16.
35. Miller G. The Adoption of Inoculation for Smallpox in England and France 1957, University of Pennsylvania Press, Philadelphia, PA.
36. Williams G. Angel of Death: The Story of Smallpox 2010, Macmillan Publishers Limited, Houndmills, England.
37. Pead P.J. Benjamin Jesty: new light in the dawn of vaccination. Lancet 2003, 362:2104-2109.
38. Hammarsten J.F., Tattersall W., Hammarsten J.E. Who discovered smallpox vaccination? Edward Jenner or Benjamin Jesty?. Trans Am Clin Climatol Assoc 1979, 90:44-55.
39. Jenner E. An Inquiry into the Causes and Effects of the Variolae Vaccinae: A Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name Cow Pox 1978, Classics of Medicine Library, Birmingham, AL.
40. Pasteur L. Vaccination in relation to chicken-cholera and splenic fever 1922, Masson et Cie, Paris, France, 370-378.
41. LeFanu W. A Bio-bibliography of Edward Jenner 1749-1823 1951, Harvey & Blythe, London, England.
42. del Castillo F.F. Los Viajes de Don Francisco Xavier de Balmis 1960, Galas de Mexico, Mexico.
43. Bowers J.Z. The Fiedlging H. Garrison Lecture: The odyssey of smallpox vaccination. Bull Hist Med 1981, 55:17-33.
44. Creighton C. The Natural History of Cow-Pox and Vaccinal Syphilis 1887, Cassell, London, England.
45. Nott J.C. Smallpox epidemic in Mobile during the winter of 1865-1866. Nashville J Med Surg 1867, 2:372-380.
46. Burroughs Wellcome The history of inoculation and vaccination for the prevention and treatment of disease: lecture memoranda, American Medical Association, 1913 1913, England: Burroughs Wellcome, London.
47. Osler W. Medical Notes. Boston Med Surg J 1910, 163:959-964.
48. Wolfe R.M., Sharp L.K. Anti-vaccinationists past and present. Br Med J 2002, 325:430-432.
49. Williams T. The Pox and the Covenant: Mather, Franklin, and the Epidemic that Changed America's Destiny 2010, Sourcebooks, Naperville, IL.
50. Edwardes E.J. A Concise History of Small-pox and Vaccination in Europe 1902, HK Lewis, London, England.
51. Galbiati G. Memoria Sulla Inoculazione Vaccina coll'Umore Ricavato Immediatement dall Vacca Precedentemente Inoculata 1810, Napoli:.
52. Congres Medical de Lyon Compterendu des travaux et des discussions. Gazette Med Lyon 1864, 19:449-471.
53. Dudgeon J.A. Development of smallpox vaccine in England in the eighteenth and nineteenth centuries. Br Med J 1963, 1:1367-1372.
54. Leavell B.S. Thomas Jefferson and smallpox vaccination. Trans Am Clin Climatol Assoc 1977, 88:119-127.
55. Best M., Katamba A., Neuhauser D. Making the right decision: Benjamin Franklin's son dies of smallpox in 1736. Qual Saf Health Care 2007, 16:478-480.
56. Markel H. Life, Liberty and the Pursuit of Vaccines. The New York Times 2011, February 28.
57. Blake J.B. Benjamin Waterhouse and the introduction of vaccination. By John B. Blake, 1957. Rev Infect Dis 1987, 9:1044-1052.
58. Hopkins D.R. Benjamin Waterhouse (1754-1846): the "Jenner of America". Am J Trop Med Hyg 1977, 26(5 pt 2 suppl):1060-1064.
59. Halsey R.H. How the President, Thomas Jefferson, and Doctor Benjamin Waterhouse established vaccination as a public health procedure 1936, New York Academy of Medicine, New York, NY.
60. Chapin C.V., Smith J. Permanency of the mild type of smallpox. J Prev Med 1932, 6:273-320.
61. Vaughan V.C. Smallpox before and after Edward Jenner. Hygeia 1923, 1:205-211.
62. Woodward S.B., Feemster R.F. The relation of smallpox morbidity to vaccination laws. N Engl J Med 1933, 208:317-318.
63. Leake J.P. Questions and answers on smallpox vaccination. Public Health Rep 1927, 42:221-238.
64. Low R.B. The Incidence of Small-pox Throughout the World in Recent Years 1918, His Majesty's Stationery Office, London, England.
65. Henneberg G. The distribution of smallpox in Europe 1919-1948. World Atlas of Epidemic Diseases, Part II 1952, 67-72. Falk-Verlag, Hamburg, Germany. E. Rodenwaldt, H.H.J. Jusatz (Eds.).
66. World Health Organization, WHO Study Group on Requirements for Smallpox Vaccine Requirements for biological substances, 5: requirements for smallpox vaccine, 1959 1959, WHO, Geneva, Switzerland, Report 180.
67. Collier L.H. The development of a stable smallpox vaccine. J Hyg (Lond) 1955, 53:76-101.
68. Rodrigues B.A. Smallpox eradication in the Americas. Bull Pan Am Health Organ 1975, 9:53-68.
69. World Health Organization Eradication of Smallpox 1958, WHO, Geneva, Switzerland, Official Record of the World Health Organization; Report 87.
70. World Health Organization Smallpox Eradication 1959, WHO, Geneva, Switzerland, Official Record of the World Health Organization; Report 95.
71. World Health Organization 1966, Report 152, WHO, Geneva, Switzerland, Official Records of the World Health Organization.
72. Henderson D.A. The eradication of smallpox. Sci Am 1976, 235:25-33.
73. World Health Organization Handbook for Smallpox Eradication in Endemic Areas 1967, World Health Organization, Geneva, Switzerland.
74. Foege W.H., Millar J.D., Lane J.M. Selective epidemiologic control in smallpox eradication. Am J Epidemiol 1971, 94:311-315.
75. Arita I., Henderson D.A. Freeze-dried vaccine for the smallpox eradication programme 1969, Yogoslav Academy of Sciences and Arts, Zagreb.
76. Arita I. The control of vaccine quality in the smallpox eradication programme. Symposia Series in Immunobiological Standardization 1973, 19:79-87.
77. Henderson D.A. A discussion on technologies for rural health: smallpox eradication. Proc R Soc Lond B Biol Sci 1977, 199:83-97.
78. Henderson D.A., Arita I., Shafa E. Studies of the Bifurcated Needle and Recommendations for Its Use 1969, World Health Organization, Geneva, Switzerland.
79. Thomas D.B., Mack T.M., Ali A., et al. Epidemiology of smallpox in West Pakistan, 3: outbreak detection and interlocality transmission. Am J Epidemiol 1972, 95:178-189.
80. Mack T.M., Thomas D.B., Ali A., et al. Epidemiology of smallpox in West Pakistan, I: acquired immunity and the distribution of disease. Am J Epidemiol 1972, 95:157-168.
81. Foege W.H., Millar J.D., Henderson D.A. Smallpox eradication in West and Central Africa. Bull World Health Organ 1975, 52:209-222.
82. Deria A., Jezek Z., Markvart K., et al. The world's last endemic case of smallpox: surveillance and containment measures. Bull World Health Organ 1980, 58:279-283.
83. Shooter R.A. Report of the Investigation into the Cause of the 1978 Birmingham Smallpox Occurrence 1980, Her Majesty's Stationery Office, London, England.
84. World Health Organization Smallpox eradication: destruction of variola virus stocks. Wkly Epidemiol Rec 1999, 74:188-191.
85. Tucker J.B. Scourge: The Once and Future Threat of Smallpox 2001, Atlantic Monthly Press, New York, NY.
86. Henderson D.A. Smallpox: The Death of a Disease: The Inside Story of Eradicating a Worldwide Killer 2009, Prometheus Books, Amherst, NY.
87. Foege W.H. House on Fire: The Fight to Eradicate Smallpox 2011, University of California Press, Berkeley, CA.
88. Basu R.N., Jezek Z., Ward N.A. The eradication of smallpox from India: History of International Public Health 1979, World Health Organization, South-East Asia Regional Office, New Delhi, India. 2nd ed.
89. Brilliant L.B. The management of smallpox eradication in India 1985, University of Michigan Press, Ann Arbor.
90. Joarder A.K., Tarantola D., Tulloch J. The eradication of smallpox from Bangladesh, New Delhi. South-East Asia Series 1980, WHO Regional Publications, Report 8.
91. Yemane T., Wickert J. Smallpox Eradication in Ethiopia: Report to the International Commission for the Certification of Smallpox Eradication 1979, International Commission for the Certification of Smallpox Eradication, Global Smallpox Eradication Programme, World Health Organization; Ministry of Health Ethiopia, Geneva, Switzerland.
92. Jezek Z., Al Aghbari M., Hatfield R. Smallpox Eradication in Somalia 1981, World Health Organization Eastern Mediterranean Regional Office and Ministry of Health, Somalia Democratic Republic, Alexandria.
93. Bazin H. The Eradication of Smallpox: Edward Jenner and the First and Only Eradication of a Human Infectious Disease 2000, Academic Press, San Diego, CA.
94. Vaccine Smallpox Eradication Supplement. Vaccine 2012, 29. S4:Entire Supplement. J. Breman, C. de Quadros, Gadelha (Eds.).
95. Kempe C.H. The end of routine smallpox vaccination in the United States. Pediatrics 1972, 49:489-492.
96. Lane J.M., Millar J.D. Routine childhood vaccination against smallpox reconsidered. N Engl J Med 1969, 281:1220-1224.
97. Multistate outbreak of monkeypox: Illinois, Indiana, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:537-540.
98. Reynolds M.G., Davidson W.B., Curns A.T., et al. Spectrum of infection and risk factors for human monkeypox, United States, 2003. Emerg Infect Dis 2007, 13:1332-1339.
99. Bernard S.M., Anderson S.A. Qualitative assessment of risk for monkeypox associated with domestic trade in certain animal species, United States. Emerg Infect Dis 2006, 12:1827-1833.
100. Fenn E.A. Pox Americana. The Great Smallpox Epidemic of 1775-82 2001, Hill and Wang, New York, NY.
101. Knollengerg B. General Amherst and germ warfare. Mississippi Valley Hist Rev 1954, 41:489-494.
102. Stone R. Public health: is live smallpox lurking in the Arctic?. Science 2002, 295:2002.
103. Harper G.J. Airborne micro-organisms: survival tests with four viruses. J Hyg (Lond) 1961, 59:479-486.
104. Wehrle P.F., Posch J., Richter K.H., et al. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ 1970, 43:669-679.
105. LeDuc J.W., Damon I., Relman D.A., et al. Smallpox research activities: US interagency collaboration, 2001. Emerg Infect Dis 2002, Jul 8:743-745.
106. Centers for Disease Control and Prevention Smallpox Vaccination Clinic Guide 2002, CDC, Atlanta, GA, September 16.
107. Martin D.B. The cause of death in smallpox: an examination of the pathology record. Mil Med 2002, 167:546-551.
108. Stanford M.M., McFadden G., Karupiah G., et al. Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol Cell Biol 2007, 85:93-102.
109. World Health Organization WHO Expert Committee on Smallpox 1964, World Health Organization, Geneva, Switzerland, Report 283.
110. Rao A.R. Smallpox 1972, The Kothari Book Depot, Bombay, India.
111. Marsden J.P., Hurst E.W. Acute perivascular myelinoclasis ("acute disseminated encephalomyelitis") in smallpox. Brain 1932, 55:181-225.
112. Moore Z.S., Seward J.F., Lane J.M. Smallpox. Lancet 2006, 367:425-435.
113. Nakano J.H. Human poxvirus diseases. Laboratory Diagnosis of Viral Infections 1985, 401-423. Marcel Dekker, New York, NY. E.H. Lennette (Ed.).
114. Hahon N. Cytopathogenicity and propagation of variola virus in tissue culture. J Immunol 1958, 81:426-432.
115. Pirsch J.B., Mika L.A., Purlson E.H. Growth characteristics of variola virus in tissue culture. J Infect Dis 1963, 113:170-178.
116. World Health Organization Guide to the Laboratory Diagnosis of Smallpox for Smallpox Eradication Programmes 1969, World Health Organization, Geneva, Switzerland.
117. Downie A.W., Saint V.L., Rao A.R., et al. Antibody response following smallpox vaccination and revaccination. J Hyg (Lond) 1969, 67:603-608.
118. Downie A.W., Saint V.L., Goldstein L., et al. Antibody response in non-haemorrhagic smallpox patients. J Hyg (Lond) 1969, 67:609-618.
119. Moyron-Quiroz J.E., McCausland M.M., Kageyama R., et al. The smallpox vaccine induces an early neutralizing IgM response. Vaccine 2009, 28:140-147.
120. Kennedy R.B., Ovsyannikova I.G., Jacobson R.M., et al. The immunology of smallpox vaccines. Curr Opin Immunol 2009, 21:314-320.
121. Kennedy R., Poland G.A. T-cell epitope discovery for variola and vaccinia viruses. Rev Med Virol 2007, 17:93-113.
122. Downie A.W., McCarthy K., MacDonald A., et al. Virus and virus antigen in the blood of smallpox patients; their significance in early diagnosis and prognosis. Lancet 1953, 265:164-166.
123. White E. Chickenpox in Kerala. Indian J Public Health 1978, 22:141-151.
124. Centers for Disease Control and Prevention Evaluating patients for smallpox: acute generalized vesicular or pustular rash illness protocol 2006, CDC, Atlanta, GA, April 18.
125. Ropp S.L., Jin Q., Knight J.C., et al. PCR strategy for identification and differentiation of small pox and other orthopoxviruses. J Clin Microbiol 1995, 33:2069-2076.
126. Espy M.J., Cockerill F.R., Meyer R.F., et al. Detection of smallpox virus DNA by LightCycler PCR. J Clin Microbiol 2002, 40:1985-1988.
127. Centers for Disease Control and Prevention Guide D: Specimen Collection and Transport Guidelines. Smallpox Response Plan and Guidelines 2006, CDC, Atlanta, GA.
128. Vistide (cidofovir injection) 2006, [package insert], Ben Venue Laboratories, Bedford, OH.
129. Bolken T.C., Hruby D.E. Tecovirimat for smallpox infections. Drugs Today (Barc) 2010, 46:109-117.
130. Yang G., Pevear D.C., Davies M.H., et al. An orally bioavailable antipoxvirus compound (ST-246 inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 2005, 79:13139-13149.
131. Huggins J., Goff A., Hensley L., et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 2009, 53:2620-2625.
132. Berhanu A., King D.S., Mosier S., et al. ST-246 inhibits in vitro poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother 2009, 53:4999-5009.
133. Grosenbach D.W., Jordan R., King D.S., et al. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 2008, 26:933-946.
134. Berhanu A., King D.S., Mosier S., et al. Impact of ST-246 on ACAM2000 smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine 2010, 29:289-303.
135. Vora S., Damon I., Fulginiti V., et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008, 46:1555-1561.
136. Centers for Disease control and Prevention Progressive vaccinia in a military smallpox vaccinee:- United States, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:532-536.
137. Baker R.O., Bray M., Huggins J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 2003, 57:13-23.
138. Kesson A.M., Ferguson J.K., Rawlinson W.D., et al. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997, 25:911-914.
139. Smee D.F., Wong M.H., Bailey K.W., et al. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int J Antimicrob Agents 2004, 23:430-437.
140. Smee D.F., Bailey K.W., Sidwell R.W. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir Chem Chemother 2000, 11:303-309.
141. Hope Simpson R.E. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952, 2:549-554.
142. de Carvalho Filho E.S., Morris L., de Lemos A.L., et al. Smallpox eradication in Brazil, 1967-69. Bull World Health Organ 1970, 43:797-807.
143. Heiner G.G., Fatima N., Daniel R.W., et al. A study of inapparent infection in smallpox. Am J Epidemiol 1971, 94:252-268.
144. Henderson R.H., Yekpe M. Smallpox transmission in Southern Dahomey: a study of a village outbreak. Am J Epidemiol 1969, 90:423-428.
145. Thomas D.B., McCormack W.M., Arita I., et al. Endemic smallpox in rural East Pakistan. I. Methodology, clinical and epidemiologic characteristics of cases, and intervillage transmission. Am J Epidemiol 1971, 93:361-372.
146. Thomas D.B., Arita I., McCormack W.M., et al. Endemic smallpox in rural East Pakistan, II: intervillage transmission and infectiousness. Am J Epidemiol 1971, 93:373-383.
147. Downie A.W., Meiklejohn M., St Vincent L., et al. The recovery of smallpox virus from patients and their environment in a smallpox hospital. Bull World Health Organ 1965, 33:615-622.
148. Mitra A.C., Sarkar J.K., Mukherjee M.K. Virus content of smallpox scabs. Bull World Health Organ 1974, 51:106-107.
149. Anders W., Posch J. Die Pockenausbrucke 1961/62 in Nordrhein-Westfalen. Bundesgesundheitbl 1962, 17:265-269.
150. Smallpox in Yugoslavia. Med J Aust 1972, 1:1063-1064.
151. Hopkins D.R., Lane J.M., Cummings E.C., et al. Two funeral-associated smallpox outbreaks in Sierra Leone. Am J Epidemiol 1971, 94:341-347.
152. Huq F. Effect of temperature and relative humidity on variola virus in crusts. Bull World Health Organ 1976, 54:710-712.
153. Kempe C.H. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960, 26:176-189.
154. Hopkins R.J., Lane J.M. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis 2004, 39:819-826.
155. Kempe C.H., Bowles C., Meiklejohn G., et al. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull World Health Organ 1961, 25:41-48.
156. Marennikova S.S. The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox. Bull World Health Organ 1962, 27:325-330.
157. Fulginiti V.A., Kempe C.H., Hathaway W.E., et al. Progressive vaccinia in immunologically deficient individuals. Birth Defects 1968, 4:129-145.
158. Copeman P.W., Wallace H.J. Eczema vaccinatum. Br Med J 1964, 2:906-908.
159. Neff J.M., Lane J.M., Pert J.H., et al. Complications of smallpox vaccination, I: national survey in the United States, 1963. N Engl J Med 1967, 276:125-132.
160. Fulginiti V.A., Winograd L.A., Jackson M., et al. Therapy of experimental vaccinal keratitis: effect of idoxuridine and VIG. Arch Ophthalmol 1965, 74:539-544.
161. Vaccinia Immune Globulin Intravenous (Human) (VIGIV) 2005, [package insert], Cangene Corp, Winnipeg, Canada.
162. Centers for Disease Control and Prevention Smallpox Fact Sheet: Medical Management of Smallpox (Vaccinia) Vaccine Adverse Reactions: Vaccinia Immune Globulin and Cidofovir 2006, CDC, Atlanta, GA, April 25.
163. Baxby D. Jenner's Smallpox Vaccine: The Riddle of Vaccinia Virus and It's Origin 1981, Heinemann Educational Books, London, England.
164. United Kingdom Ministry of Health Report of the Committee on Vaccination 1928, His Majesty's Stationery Office, London, England.
165. Turner G.S., Squires E.J., Murray H.G. Inactivated smallpox vaccine: a comparison of inactivation methods. J Hyg (Lond) 1970, 68:197-210.
166. Makarevich V.G., Laznikova T.N., Gutnikova M.N., et al. Study of the products of biosynthesis of the mutant of Act. aureofaciens 1515 [in Russian]. Antibiotiki 1966, 11:980-984.
167. Boulter E.A., Zwartouw H.T., Titmuss D.H., et al. The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am J Epidemiol 1971, 94:612-620.
168. Amies C.R. Loss of immunogenic properties of vaccinia virus inactivated by formaldehyde. Can J Microbiol 1961, 7:141-152.
169. Moss B. Poxvirus entry and membrane fusion. Virology 2006, 344:48-54.
170. Amanna I.J., Slifka M.K., Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006, 211:320-337.
171. Moss B. Smallpox vaccines: targets of protective immunity. Immunol Rev 2011, 239:8-26.
172. Rivers T.M. With the Technical Assistance of S.M.Ward. Cultivation of vaccine virus for Jennerian prophylaxis. J Exp Med 1931, 54:453-461.
173. Kempe C.H., Fulginiti V., Minamitani M., et al. Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78). Pediatrics 1968, 42:980-985.
174. van der Noordaa J., Dekking F., Posthuma J., et al. Primary vaccination with an attenuated strain of vaccinia virus. Arch Gesamte Virusforsch 1967, 22:210-214.
175. Tint H. The rationale for prevaccination with attenuated vaccine (CV-178) in preventing some vaccination complications. International Symposium on Smallpox Vaccine: Symposia Series in Immunobiological Standardization 1973, 19:281-292.
176. Galasso G.J., Mattheis M.J., Cherry J.D., et al. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration: summary. J Infect Dis 1977, 135:183-186.
177. McIntosh K. A comparative study of four smallpox vaccines in children 1985, 77-84. Elsevier, New York, NY. G.V. Quinnan (Ed.).
178. Hochstein-Mintzel V., Hanichen T., Huber H.C., et al. An attenuated strain of vaccinia virus (MVA): successful intramuscular immunization against vaccinia and variola (author's transl) [in German]. Zentralbl Bakteriol Orig A 1975, 230:283-297.
179. Stickl H., Hochstein-Mintzel V., Mayr A., et al. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl) [in German]. Dtsch Med Wochenschr 1974, 99:2386-2392.
180. Mayr A., Hochstein-Mintzel V., Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-stammes MVA. Infection 1975, 3:6-14.
181. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992, 89:10847-10851.
182. Nicolau A.R. Results of the use of smallpox vaccine prepared on chick embryo chorio-allantoic membrane [in Portuguese]. Hospital (Rio J) 1961, 59:293-300.
183. Hekker A.C., Bos J.M., Smith L.A. Stable freeze-dried smallpox vaccine made in monolayer cultures of primary rabbit kidney cells. J Biol Stand 1973, 1:21-32.
184. Hekker A.C., Bos J.M., Rai N.K., et al. Large-scale use of freeze-dried smallpox vaccine prepared in primary cultures of rabbit kidney cells. Bull World Health Organ 1976, 54:279-284.
185. Greenberg R.N., Kennedy J.S. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008, 17:555-564.
186. Kennedy J.S., Greenberg R.N. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009, 8:13-24.
187. US Department of Health and Human Services Project Bioshield Annual Report to Congress 2009, DHHS, Washington, DC.
188. FDA Fast Track status for IMVAMUNE. Hum Vaccin 2010, 6.
189. Kaketsuken The Chemo-Sero-Therapeutic Research Institute Kaketsuken Awarded HHS Contract Valued at up to $34 Million for the Development of a Live Attenuated Smallpox Vaccine (LC16m8) 2011, [press release], Kaketsuken, Kumamoto, Japan, January 12.
190. Gassmann R., Engler O.B., Steffen R., et al. Clinical and immune response to undiluted and diluted smallpox vaccine. Swiss Med Wkly 2008, 138:392-397. Jul 12.
191. Couch R.B., Winokur P., Edwards K.M., et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J Infect Dis 2007, 195:826-832.
192. Kim S.H., Yeo S.G., Jang H.C., et al. Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial. J Infect Dis 2005, 192:1066-1070.
193. Hsieh S.M., Chen S.Y., Sheu G.C., et al. Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain. Vaccine 2006, 24:510-515.
194. Talbot T.R., Stapleton J.T., Brady R.C., et al. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 2004, 292:1205-1212.
195. Rock M.T., Yoder S.M., Talbot T.R., et al. Cellular immune responses to diluted and undiluted Aventis Pasteur smallpox vaccine. J Infect Dis 2006, 194:435-443.
196. Belshe R.B., Newman F.K., Frey S.E., et al. Dose-dependent neutralizing-antibody responses to vaccinia. J Infect Dis 2004, 189:493-497.
197. Frey S.E., Couch R.B., Tacket C.O., et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002, 346:1265-1274. Apr.
198. Winter P.A., Mason J.H., Kuhr E., et al. Combined immunization against poliomyelitis, diphtheria, whooping cough, tetanus and smallpox. S Afr Med J 1963, 37:513-515.
199. Karchmer A.W., Friedman J.P., Casey H.L. Simultaneous administration of live virus vaccines, measles, mumps, poliomyelitis, and smallpox. Am J Dis Child 1971, 121:382-388.
200. Meers P.D. Further observations on 17D-yellow fever vaccination by scarification, with and without simultaneous smallpox vaccination. Trans R Soc Trop Med Hyg 1960, 54:493-501.
201. Breman J.G., Coffi E., Bomba-Ire R., et al. Evaluation of a measles-smallpox vaccination campaign by a sero-epidemiologic method. Am J Epidemiol 1975, 102:564-571.
202. Meyer H.M., Hostetler D.D., Bernhein B.C., et al. Response of Volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines. Bull World Health Organ 1964, 30:783-794.
203. Ruben F.L., Smith E.A., Foster S.O., et al. Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children. Bull World Health Organ 1973, 48:175-181.
204. Foege W.H., Foster S.O. Multiple antigen vaccine strategies in developing countries. Am J Trop Med Hyg 1974, 23:685-689.
205. Wharton M., Strikas R.A., Harpaz R., et al. Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003, 52(RR-7):1-16.
206. Rotz L.D., Dotson D.A., Damon I.K., et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001, 50(RR-10):1-25.
207. Olmsted S.S., Grabenstein J.D., Jain A.K., et al. Use of an electronic monitoring system for self-reporting smallpox vaccine reactions. Biosecur Bioterror 2005, 3:198-206.
208. Neff J.M., Lane J.M., Fulginiti V.A., et al. Contact vaccinia: transmission of vaccinia from smallpox vaccination. JAMA 2002, 288:1901-1905.
209. Talbot T.R., Ziel E., Doersam J.K., et al. Risk of vaccinia transfer to the hands of vaccinated persons after smallpox immunization. Clin Infect Dis 2004, 38:536-541.
210. Hepburn M.J., Dooley D.P., Murray C.K., et al. Frequency of vaccinia virus isolation on semipermeable versus nonocclusive dressings covering smallpox vaccination sites in hospital personnel. Am J Infect Control 2004, 32:126-130.
211. Waibel K.H., Ager E.P., Topolski R.L., et al. Randomized trial comparing vaccinia on the external surfaces of 3 conventional bandages applied to smallpox vaccination sites in primary vaccinees. Clin Infect Dis 2004, 39:1004-1007.
212. Poland G.A., Grabenstein J.D., Neff J.M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005, 23:2078-2081.
213. Savitz S., Stewart J. Lessons learned from smallpox vaccination of US Navy forces before Operation Iraqi Freedom. Mil Med 2007, 172:353-358.
214. Folio L.R., Yao E.F. US military smallpox vaccination program: occupational impact of immunizations on aircrew in Air Mobility Command, US Air Force. J Am Osteopath Assoc 2007, 107:547-553.
215. Cross R.M., Kaplan C., McClean D. The heat resistance of dried smallpox vaccine. Lancet 1957, 272:446-448.
216. Madeleine M.M., Brumback B., Cushing-Haugen K.L., et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis 2002, 186:1565-1574.
217. Kline R.L., Regnery R.L., Armstrong G.L., et al. Stability of diluted smallpox vaccine under simulated clinical conditions. Vaccine 2005, 23:4944-4946.
218. Blattner R.J., Norman J.O., Heys F.M., et al. Antibody response to cutaneous inoculation with vaccinia virus: viremia and viruria in vaccinated children. J Pediatr 1964, 64:839-852.
219. Gins H.A., Hackenthal H., Kamentzewa N. Experimentelle Untersuchungen fiber die Generalisierung des Vaccine-Virus beim Menschen und Versuchstier. Z Hyg Infektionskr 1929, 110:429-441.
220. Cummings J.F., Polhemus M.E., Hawkes C., et al. Lack of vaccinia viremia after smallpox vaccination. Clin Infect Dis 2004, 38:456-458.
221. Klote M.M., Ludwig G.V., Ulrich M.P., et al. Absence of oropharyngeal vaccinia virus after vaccinia (smallpox) vaccination. Ann Allergy Asthma Immunol 2005, 94:682-685.
222. Pincus W.B., Flick J.A. The role of hypersensitivity in the pathogenesis of vaccinia virus infection in humans. J Pediatr 1963, 62:57-62.
223. McCarthy K., Downie A.W., Bradley W.H. The antibody response in man following infection with viruses of the pox group, II: antibody response following vaccination. J Hyg 1958, 56:466-478.
224. Sonoda S., Nakayama T. Detection of measles virus genome in lymphocytes from asymptomatic healthy children. J Med Virol 2001, 65:381-387.
225. Kim S.H., Choi S.J., Park W.B., et al. Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 2007, 25:6287-6291.
226. Xu R., Johnson A.J., Liggitt D., et al. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004, 172:6265-6271.
227. Hanna W., Baxby D. Studies in smallpox and vaccination, 1913. Rev Med Virol 2002, 12:201-209.
228. Heiner G.G., Fatima N., McCrumb F.R. A study of intrafamilial transmission of smallpox. Am J Epidemiol 1971, 94:316-326.
229. Mortimer P.P. Can postexposure vaccination against smallpox succeed?. Clin Infect Dis 2003, 36:622-629.
230. Shearer J.D., Siemann L., Gerkovich M., et al. Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection. Antimicrob Agents Chemother 2005, 49:2634-2641.
231. Lustig S., Maik-Rachline G., Paran N., et al. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 2009, 27:1691-1699.
232. Chen Z., Earl P., Americo J., et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A 2006, 103:1882-1887.
233. McCausland M.M., Benhnia M.R., Crickard L., et al. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir Ther 2010, 15:661-675.
234. Belyakov I.M., Earl P., Dzutsev A., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 2003, 100:9458-9463.
235. Chaudhri G., Panchanathan V., Bluethmann H., et al. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 2006, 80:6339-6344.
236. Panchanathan V., Chaudhri G., Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol 2006, 80:6333-6338.
237. Kennedy R.B., Ovsyannikova I.G., Pankratz V.S., et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009, 27:3319-3323.
238. Davis N.A., Crowe J.E., Pajewski N.M., et al. Surfing a genetic association interaction network to identify modulators of antibody response to smallpox vaccine. Genes Immun 2010, 11:630-636.
239. Stanley S.L., Frey S.E., Taillon-Miller P., et al. The immunogenetics of smallpox vaccination. J Infect Dis 2007, 196:212-219.
240. Rubins K.H., Hensley L.E., Jahrling P.B., et al. The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A 2004, 101:15190-15195.
241. Oberg A.L., Dhiman N., Grill D.E., et al. Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman low density immune arrays. J Immunol Methods 2011, 366:69-78.
242. Yang Z., Bruno D.P., Martens C.A., et al. Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A 2010, 107:11513-11518.
243. Satheshkumar P.S., Moss B. Poxvirus transcriptome analysis. Proc Natl Acad Sci U S A 2008, 105:E62-E64.
244. Assarsson E., Greenbaum J.A., Sundstrom M., et al. Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 2008, 105:2140-2145.
245. Kennedy R., Pankratz V.S., Swanson E., et al. Statistical approach to estimate vaccinia- specific neutralizing antibody titers using a high throughput assay. Clin Vaccine Immunol 2009, 16:1105-1112.
246. Kotturi M.F., Assarsson E., Peters B., et al. Of mice and humans: how good are HLA transgenic mice as a model of human immune responses?. Immunome Res 2009, 5:3.
247. Americo J.L., Moss B., Earl P.L. Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J Virol 2010, 84:8172-8180.
248. Rubins K.H., Hensley L.E., Bell G.W., et al. Comparative analysis of viral gene expression programs during poxvirus infection: a transcriptional map of the vaccinia and monkeypox genomes. PLoS ONE 2008, 3:e2628. doi:10.1371/journal.pone.0002628.
249. Nalca A., Nichols D.K. Rabbitpox: a model of airborne transmission of smallpox. J Gen Virol 2011, 92(pt 1):31-35.
250. Chapman J.L., Nichols D.K., Martinez M.J., et al. Animal models of orthopoxvirus infection. Vet Pathol 2010, 47:852-870.
251. Schultz D.A., Sagartz J.E., Huso D.L., et al. Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology 2009, 383:86-92.
252. Kramski M., Mätz-Rensing K., Stahl-Hennig C., et al. A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection. PLoS ONE 2010, 5:e10412. doi:10.1371/journal.pone.0010412.
253. Zhang C.X., Sauder C., Malik T., et al. A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines. Biologicals 2010, 38:278-283.
254. Parker S., Siddiqui A.M., Oberle C., et al. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 2009, 385:11-21.
255. Johnson R.F., Yellayi S., Cann J.A., et al. Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox. Virology 2011, 418:102-112.
256. Viner K.M., Isaacs S.N. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect 2005, 7:579-583.
257. Karem K.L., Reynolds M., Braden Z., et al. Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol 2005, 12:867-872.
258. Brilliant L.B., Nakano J.H., Kitamura T., et al. Occupationally-acquired smallpox in an IgM-deficient health worker. Bull World Health Organ 1981, 59:99-106.
259. Mayumi M., Yamaoka K., Tsutsui T., et al. Selective immunoglobulin M deficiency associated with disseminated molluscum contagiosum. Eur J Pediatr 1986, 145:99-103.
260. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
261. Hammarlund E., Lewis M.W., Hansen S.G., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
262. Taub D.D., Ershler W.B., Janowski M., et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008, 121:1058-1064.
263. Crotty S., Felgner P., Davies H., et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171:4969-4973.
264. Frey S.E., Newman F.K., Yan L., et al. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003, 289:3295-3299.
265. Frey S.E., Newman F.K., Cruz J., et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002, 346:1275-1280.
266. Nishiura H., Eichner M. Estimation of the duration of vaccine-induced residual protection against severe and fatal smallpox based on secondary vaccination failure. Infection 2006, 34:241-246.
267. Nishiura H., Schwehm M., Eichner M. Still protected against smallpox? Estimation of the duration of vaccine-induced immunity against smallpox. Epidemiology 2006, 17:576-581.
268. + T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28:710-722.
269. Demkowicz W.E., Littaua R.A., Wang J., et al. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996, 70:2627-2631.
270. Frelinger J.A., Garba M.L. Responses to smallpox vaccine. N Engl J Med 2002, 347:689-690.
271. Hammarlund E., Lewis M.W., Hanifin J.M., et al. Antiviral immunity following smallpox virus infection: a case-control study. J Virol 2010, 84:12754-12760.
272. Combadiere B., Boissonnas A., Carcelain G., et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004, 199:1585-1593.
273. Kennedy J.S., Frey S.E., Yan L., et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 2004, 190:1286-1294.
274. Amara R.R., Nigam P., Sharma S., et al. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 2004, 78:3811-3816.
275. + T cell responses. J Exp Med 2007, 204:1405-1416.
276. Edghill-Smith Y., Golding H., Manischewitz J., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005, 11:740-747.
277. Drexler I., Staib C., Kastenmuller W., et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A 2003, 100:217-222.
278. + T-cell peptide epitope of vaccinia and variola viruses. J Virol 2004, 78:7052-7060.
279. + T-cell epitopes in the murine intranasal challenge model. Eur J Immunol 2009, 39:717-722.
280. Schmid K., Keasey S.L., Pittman P., et al. Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome. Proteomics Clin Appl 2008, 2:1528-1538.
281. Davies D.H., Molina D.M., Wrammert J., et al. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 2007, 7:1678-1686.
282. Davies D.H., Wyatt L.S., Newman F.K., et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J Virol 2008, 82:652-663.
283. Benhnia M.R., McCausland M.M., Su H.P., et al. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 2008, 82:3751-3768.
284. Davies D.H., Liang X., Hernandez J.E., et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A 2005, 102:547-552.
285. Lopez A.S., Burnett-Hartman A., Nambiar R., et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008, 197:646-653.
286. + T cell epitopes in vaccinated rhesus macaques. Vaccine 2009, 27:4990-5000.
287. + T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005, 201:95-104.
288. Jing L., Chong T.M., McClurkan C.L., et al. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol 2005, 175:7550-7559.
289. Oseroff C., Kos F., Bui H.H., et al. HLA class I- restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A 2005, 102:13980-13985.
290. + T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Hum Immunol 2006, 67:512-520.
291. Hansen S., Stamm-Balderjahn S., Zuschneid I., et al. Closure of medical departments during nosocomial outbreaks: data from a systematic analysis of the literature. J Hosp Infect 2007, 65:348-353.
292. Johnson K.L., Ovsyannikova I.G., Mason C.J., et al. Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine 2009, 28:38-47.
293. Pasquetto V., Bui H.H., Giannino R., et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol 2005, 175:5504-5515.
294. Kennedy R.B., Poland G.A. The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins. Virology 2010, 408:232-240.
295. Jing L., Davies D.H., Chong T.M., et al. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol 2008, 82:7120-7134.
296. + CTL epitopes with distinct functional profiles. J Immunol 2005, 174:2212-2219.
297. + T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum Immunol 2008, 69:815-825.
298. Jing L., Chong T.M., Byrd B., et al. Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J Immunol 2007, 178:6374-6386.
299. + cytotoxic T lymphocyte responses to a novel epitope in vaccinia virus that is conserved among orthopox viruses. J Infect Dis 2006, 194:168-175.
300. + T cells from a vaccinated donor. J Proteome Res 2008, 7:2703-2711.
301. + T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003, 197:927-932.
302. + T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins A24R and D1R conserved among poxviruses. J Immunol 2007, 179:1303-1312.
303. + T-cell determinants and cross-reactivity in BALB/c mice. J Virol 2006, 80:6318-6323.
304. Oseroff C., Peters B., Pasquetto V., et al. Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve. J Immunol 2008, 180:7193-7202.
305. Jing L., McCaughey S.M., Davies D.H., et al. ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods 2009, 347:36-45.
306. Moise L., McMurry J.A., Buus S., et al. In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine 2009, 27:6471-6479.
307. + T cell response to the vaccinia protective antigens B5R and A33R. Mol Immunol 2009, 46:1481-1487.
308. + T cell responses. J Immunol 2007, 178:6814-6820.
309. Sette A., Grey H., Oseroff C., et al. Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 2009, 27(suppl 6):G21-G26.
310. Tang J., Murtadha M., Schnell M., et al. Human T-cell responses to vaccinia virus envelope proteins. J Virol 2006, 80:10010-10020.
311. + T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 2009, 90(pt 2):468-480.
312. Vita R., Zarebski L., Greenbaum J.A., et al. The immune epitope database 2.0. Nucleic Acids Res 2010, 38(database issue):D854-D862.
313. Moutaftsi M., Tscharke D.C., Vaughan K., et al. Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol 2010, 5:221-239.
314. + T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 2008, 28:847-858.
315. Panchanathan V., Chaudhri G., Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand?. Immunol Cell Biol 2008, 86:80-86.
316. Gallwitz S., Schutzbank T., Heberling R.L., et al. Smallpox: residual antibody after vaccination. J Clin Microbiol 2003, 41:4068-4070.
317. Sarkar J.K., Mitra A.C., Mukherjee M.K. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975, 52:307-311.
318. Mack T.M., Noble J., Thomas D.B. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972, 21:214-218.
319. Barry F.W. Report on an Epidemic of Smallpox in Shefield, 1887-8 1889, H.M. Stationery Office, London, England.
320. Grabenstein J.D., Winkenwerder W. US military smallpox vaccination program experience. JAMA 2003, 289:3278-3282.
321. Metzger W., Mordmueller B.G. Vaccines for preventing smallpox. Cochrane Database Syst Rev 2007, CD004913.
322. Strikas R.A., Neff L.J., Rotz L., et al. US Civilian Smallpox Preparedness and Response Program, 2003. Clin Infect Dis 2008, 46(suppl 3):S157-S167.
323. Arita I. Duration of immunity after smallpox vaccination: a study on vaccination policy against smallpox bioterrorism in Japan. Jpn J Infect Dis 2002, 55:112-116.
324. Zikmund V., Das N., Krishnayengar R., et al. Contribution to the problem of challenge vaccination: observations on vaccination of cured smallpox cases in India in 1971, 1972 and 1973. Indian J Public Health 1978, 22:102-106.
325. Mack T.M. Smallpox in Europe, 1950-1971. J Infect Dis 1972, 125:161-169.
326. Marsden J.P. Variola minor, a personal analysis of 13,686 cases. Bull Hyg 1948, 23:735.
327. Kim S.H., Yeo S.G., Park K.H., et al. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination. Clin Microbiol Infect 2007, 13:91-93.
328. Nishiura H., Eichner M. Predicting residual immunity against smallpox. J Infect Dis 2007, 195:160-161.
329. Hatakeyama S., Moriya K., Saijo M., et al. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations. Clin Diagn Lab Immunol 2005, 12:520-524.
330. Downie A.W., McCarthy K. The antibody response in man following infection with viruses of the pox group, III: antibody response in smallpox. J Hyg (Lond) 1958, 56:479-487.
331. Neff J., Modlin J., Birkhead G.S., et al. Monitoring the safety of a smallpox vaccination program in the United States: report of the Joint Smallpox Vaccine Safety Working Group of the Advisory Committee on Immunization Practices and the Armed Forces Epidemiological Board. Clin Infect Dis 2008, 46(suppl 3):S258-S270.
332. Brainerd H.D., Hanna L., Jawetz E. Methisazone in progressive vaccinia. N Engl J Med 1967, 276:620-692.
333. De C.E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002, 55:1-13.
334. Casey C.G., Iskander J.K., Roper M.H., et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 2005, 294:2734-2743.
335. Ruben F.L., Lane J.M. Ocular vaccinia: an epidemiologic analysis of 348 cases. Arch Ophthalmol 1970, 84:45-48.
336. Sejvar J.J., Labutta R.J., Chapman L.E., et al. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 2005, 294:2744-2750.
337. Wilson G.S. The Hazard of Immunization 1967, Athlone Press, London, England.
338. DeVries E. Postvaccinial Perivenous Encephalitis. A Pathological Anatomical Study on the Place of Postvaccinial Perivenous Encephalitis in the Group Encephalitides (the Disease of Turnbull-Lucksch-Bastiaanse) 1960, Elsevier, Amsterdam, the Netherlands.
339. Weber G., Lange J. On the variation in "incubation time" of postvaccinal cerebral disease [in German]. Dtsch Med Wochenschr 1961, 86:1461-1468.
340. Polak M.F. Complications of smallpox vaccination in the Netherlands, 1959-1970. Series in Immunobiological Standardization 1973, 19:235-242.
341. Berger K., Puntigam F. Incidence of postvaccinal encephalitis in children of different ages after first vaccination [in German]. Wien Med Wochenschr 1954, 104:487-492.
342. Conybeare E.T. Illnesses attributed to smallpox vaccination, 1951-60, II: illnesses reported as affecting the central nervous system. Mon Bull Minist Health Public Health Lab Serv 1964, 23:150-160.
343. Herrlich A. The problems of smallpox and smallpox vaccination [in undetermined language]. Munch Med Wochenschr 1954, 96:529-533.
344. Stuart G. Post-vaccinal encephalitis: memorandum on post-vaccinal encephalitis. Bull World Health Organ 1948, 1:36-53.
345. Femmer J. Hazards of Immunization 1967, cited by Wilson GS, Athlone Press, London, England.
346. Seeleman K. Zerebrale Komplikationen nach Pock-enschutzimpfungen mit besonderer Berucksichtigung der Alterdisposition in Hamburg 1936 bis 1958. Dtsch Med Wochenschr 1960, 85:1081-1089.
347. van den Berg C.A. L'encephalite post-vaccinale aux Pays-Bas. Bull Office Intern Hyg Publique 1946, 38:847-848.
348. Lane J.M., Ruben F.L., Neff J.M., et al. Complications of smallpox vaccination, 1968. N Engl J Med 1969, 281:1201-1208.
349. Lane J.M., Ruben F.L., Neff J.M., et al. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970, 122:303-309.
350. Berger K., Heinrich W. Decrease in postvaccinal deaths in Austria after introducing a less pathogenic virus strain. International Symposium on Smallpox Vaccine: Symposia Series in Immunobiological Standardization 1973, 199-203.
351. Marennikova S.S., Chimishkyan K.L., Maltseva N.N., et al. Characteristics of virus strains for production of smallpox vaccines 1969, 65-79. Academy of Sciences and Arts, Zagreb, Yugoslavia. B. Gusic (Ed.).
352. Karjalainen J., Heikkila J., Nieminen M.S., et al. Etiology of mild acute infectious myocarditis: relation to clinical features. Acta Med Scand 1983, 213:65-73.
353. Arness M.K., Eckart R.E., Love S.S., et al. Myopericarditis following smallpox vaccination. Am J Epidemiol 2004, 160:642-651.
354. Eckart R.E., Love S.S., Atwood J.E., et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004, 44:201-205.
355. Halsell J.S., Riddle J.R., Atwood J.E., et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003, 289:3283-3289.
356. Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003, 52:282-284.
357. Eckart R.E., Shry E.A., Atwood J.E., et al. Smallpox vaccination and ischemic coronary events in healthy adults. Vaccine 2007, 25:8359-8364.
358. Communicable Disease Center Manual of Operations: West and Central Africa Smallpox Eradication/Measles Control Program 1966, Communicable Disease Center, Atlanta, GA.
359. Women with smallpox vaccine exposure during pregnancy reported to the National Smallpox Vaccine in Pregnancy Registry: United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:386-388.
360. Bellows M.T., Hyman M.E., Merritt K.K. Effect of smallpox vaccination on the outcome of pregnancy. Public Health Rep 1949, 64:319-323.
361. Abramowitz L.J. Vaccination and virus diseases during pregnancy. S Afr Med J 1957, 31:1-3.
362. Bourke G.J., Whitty R.J. Smallpox vaccination in pregnancy: a prospective study. Br Med J 1964, 1:1544-1546.
363. Tondury G., Foukas M. Die Gefahrdung des menschlichen Keimlings durch Pockenimpfung in Graviditate. Pathol Microbiol 1964, 27:602-623.
364. Marmelzat W.L. Malignant tumors in smallpox vaccination scars: a report of 24 cases. Arch Dermatol 1968, 97:400-406.
365. Sewall S. Vaccinia osteomyelitis: report of a case with isolation of the vaccinia virus. Bull Hosp Jt Dis 1949, 10:59-63.
366. Cooney E.L., Collier A.C., Greenberg P.D., et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991, 337:567-572.
367. Neff J.M., Levine R.H., Lane J.M., et al. Complications of smallpox vaccination United States 1963, II: results obtained by four statewide surveys. Pediatrics 1967, 39:916-923.
368. Greenberg M. Complications of vaccination against smallpox. Am J Dis Child 1948, 76:492-502.
369. Secondary and tertiary transfer of vaccinia virus among US military personnel: United States and worldwide, 2002-2004. MMWR Morb Mortal Wkly Rep 2004, 53:103-105.
370. Raimer S.S. Managing pediatric atopic dermatitis. Clin Pediatr (Phila) 2000, 39:1-14.
371. Habbick B.F., Pizzichini M.M., Taylor B., et al. Prevalence of asthma, rhinitis and eczema among children in 2 Canadian cities: the International Study of Asthma and Allergies in Childhood. CMAJ 1999, 160:1824-1828.
372. Laughter D., Istvan J.A., Tofte S.J., et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000, 43:649-655.
373. Centers for Disease Control and Prevention HIV/AIDS Surveillance Report, Volume 16: Cases of HIV Infection and AIDS in the United States, 2004 2004, CDC, Atlanta, GA, Report 16.
374. OPTN/SRTR Transplants by Organ and Donor Type, 1995 to 2004 2005.
375. National Institutes of Health Estimated U.S. Cancer Prevalence Counts: Who Are Our Cancer Survivors in the U.S.? 2005, NIH, Bethesda, MD.
376. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778-799.
377. Urner J.A. Some observations of the vaccination of pregnant women and newborn infants. Am J Obstet Gynecol 1927, 13:70-76.
378. Lieberman B.L. Vaccination of pregnant women and newborn infants. Am J Obstet Gynecol 1927, 14:217-220.
379. Donnally H.H., Nicholson M.M. A study of vaccination in five hundred newborn infants. J Am Med Assoc 1934, 103:1269-1275.
380. Lin H.T. A study of the effect of simultaneous vaccination with BCG and smallpox vaccine in new born infants. Bull World Health Organ 1965, 33:321-336.
381. Chapman L.E., Mootrey G.T., Neff L.J. Introduction: vaccination against smallpox in the posteradication era. Clin Infect Dis 2008, 46(suppl 3):S153-S156.
382. Chapman L.E., Iskander J.K., Chen R.T., et al. A process for sentinel case review to assess causal relationships between smallpox vaccination and adverse outcomes, 2003-2004. Clin Infect Dis 2008, 46(suppl 3):S271-S293.
383. Casey C., Vellozzi C., Mootrey G.T., et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep 2006, 55(RR-1):1-16.
384. Tasker S.A., Schnepf G.A., Lim M., et al. Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis 2004, 38:1320-1322.
385. Cosma A., Nagaraj R., Staib C., et al. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retroviruses 2007, 23:782-793.
386. Edghill-Smith Y., Venzon D., Karpova T., et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis 2003, 188:1181-1191.
387. Centers for Disease Control and Prevention Smallpox Vaccination and Adverse Events Training Module 2002, January 3, 2012. http://www.bt.cdc.gov/training/smallpoxvaccine/reactions/#.
388. Webster I.M. The response of leprosy patients to small-pox vaccine. West Afr Med J 1959, 8:322-324.
389. Browne S.G., Davis E.M. Reaction in leprosy precipitated by smallpox vaccination. Lepr Rev 1962, 33:252-254.
390. Cardiac deaths after a mass smallpox vaccination campaign: New York City, 1947. MMWR Morb Mortal Wkly Rep 2003, 52:933-936.
391. Thorpe L.E., Mostashari F., Karpati A.M., et al. Mass smallpox vaccination and cardiac deaths, New York City, 1947. Emerg Infect Dis 2004, 10:917-920.
392. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible: final rule. Fed Regist 2002, 67:37988-37998.
393. Osborne J.D., Da Silva M., Frace A.M., et al. Genomic differences of vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent clone-3. Vaccine 2007, 25:8807-8832.
394. Monath T.P., Caldwell J.R., Mundt W., et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain): a second-generation smallpox vaccine for biological defense. Int J Infect Dis 2004, 8(suppl 2):S31-S44.
395. Frey S.E., Newman F.K., Kennedy J.S., et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 2009, 27:1637-1644.
396. Nalca A., Zumbrun E.E. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther 2010, 4:71-79.
397. Greenberg R.N., Kennedy J.S., Clanton D.J., et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005, 365:398-409.
398. Jang H.C., Kim C.J., Kim K.H., et al. A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers. Vaccine 2010, 28:5845-5849.
399. Hashizume S. A new attenuated strain of vaccinia virus, L 16m8: basic information [in Japanese]. J Clin Virol 1975, 3:229-235.
400. Hashizume S., Yoshizawa H., Morita M., et al. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain 1985, Elsevier, New York, NY. C.G. Quinnan (Ed.).
401. Kato S. Low neurovirulent variant of Lister strain of vaccinia virus 1985, 85-86. Elsevier, New York, NY. C.G. Quinnan (Ed.).
402. Japan Ministry of Health Report of Committee on Smallpox Vaccination. J Clin Virol 1975, 3:269-278.
403. Kidokoro M., Tashiro M., Shida H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A 2005, 102:4152-4157.
404. Saito T., Fujii T., Kanatani Y., et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 2009, 301:1025-1033.
405. Saijo M., Ami Y., Suzaki Y., et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol 2006, 80:5179-5188.
406. Morikawa S., Sakiyama T., Hasegawa H., et al. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J Virol 2005, 79:11873-11891.
407. Empig C., Kenner J.R., Perret-Gentil M., et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 2006, 24:3686-3694.
408. Mayr A., Stickl H., Muller H.K., et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl) [in German]. Zentralbl Bakteriol B 1978, 167:375-390.
409. Vollmar J., Arndtz N., Eckl K.M., et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006, 24:2065-2070.
410. Stittelaar K.J., van Amerongen G., Kondova I., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005, 79:7845-7851.
411. Stickl H.A. Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine "MVA". Prev Med 1974, 3:97-101.
412. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991, 72(pt 5):1031-1038.
413. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238:198-211.
414. Parrino J., McCurdy L.H., Larkin B.D., et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007, 25:1513-1525.
415. Seaman M.S., Wilck M.B., Baden L.R., et al. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis 2010, 201:1353-1360.
416. von Krempelhuber A., Vollmar J., Pokorny R., et al. A randomized, double-blind, dose-finding phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010, 28:1209-1216.
417. Frey S.E., Newman F.K., Kennedy J.S., et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007, 25:8562-8573.
418. Wilck M.B., Seaman M.S., Baden L.R., et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010, 201:1361-1370.
419. Buller R.M., Smith G.L., Cremer K., et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985, 317:813-815.
420. Buller R.M., Palumbo G.J. Poxvirus pathogenesis. Microbiol Rev 1991, 55:80-122.
421. Lee M.S., Roos J.M., McGuigan L.C., et al. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J Virol 1992, 66:2617-2630.
422. Tartaglia J., Perkus M.E., Taylor J., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992, 188:217-232.
423. Konishi E., Pincus S., Paoletti E., et al. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 1992, 190:454-458.
424. Stephensen C.B., Welter J., Thaker S.R., et al. Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection. J Virol 1997, 71:1506-1513.
425. Ober B.T., Bruhl P., Schmidt M., et al. Immunogenicity and safety of defective vaccinia virus Lister: comparison with modified vaccinia virus Ankara. J Virol 2002, 76:7713-7723.
426. Midgley C.M., Putz M.M., Weber J.N., et al. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol 2008, 89(pt 12):2992-2997.
427. Coulibaly S., Bruhl P., Mayrhofer J., et al. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005, 341:91-101.
428. Fogg C., Lustig S., Whitbeck J.C., et al. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 2004, 78:10230-10237.
429. Pulford D.J., Gates A., Bridge S.H., et al. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 2004, 22:3358-3366.
430. Hooper J.W., Thompson E., Wilhelmsen C., et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 2004, 78:4433-4443.
431. Moise L., Buller R.M., Schriewer J., et al. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011, 29:501-511.
432. Hooper J.W., Golden J.W., Ferro A.M., et al. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 2007, 25:1814-1823.
433. Golovkin M., Spitsin S., Andrianov V., et al. Smallpox subunit vaccine produced in Planta confers protection in mice. Proc Natl Acad Sci U S A 2007, 104:6864-6869.
434. Bielinska A.U., Chepurnov A.A., Landers J.J., et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin Vaccine Immunol 2008, 15:348-358.
435. Johnson K.L., Ovsyannikova I.G., Madden B.J., et al. Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. J Am Soc Mass Spectrom 2005, 16:1812-1817.
436. Ovsyannikova I.G., Johnson K.L., Bergen H.R., et al. Mass spectrometry and peptide-based vaccine development. Clin Pharmacol Ther 2007, 82:644-652.
437. Formenty P., Muntasir M.O., Damon I., et al. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. Emerg Infect Dis 2010, 16:1539-1545.
438. Rimoin A.W., Mulembakani P.M., Johnston S.C., et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 2010, 107:16262-16267.
439. From the Centers for Disease Control and Prevention Multistate outbreak of monkeypox: Illinois, Indiana, and Wisconsin, 2003. JAMA 2003, 290:30-31.
440. de Souza T.G., Drumond B.P., Guedes M.I., et al. Zoonotic vaccinia virus infection in Brazil: clinical description and implications for health professionals. J Clin Microbiol 2007, 45:1370-1372.
441. Leite J.A., Drumond B.P., Trindade G.S., et al. Passatempo virus, a vaccinia virus strain, Brazil. Emerg Infect Dis 2005, 11:1935-1938.
442. Silva-Fernandes A.T., Travassos C.E., Ferreira J.M., et al. Natural human infections with vaccinia virus during bovine vaccinia outbreaks. J Clin Virol 2009, 44:308-313.
443. Singh R.K., Hosamani M., Balamurugan V., et al. Buffalopox: an emerging and re-emerging zoonosis. Anim Health Res Rev 2007, 8:105-114.
444. Kurth A., Straube M., Kuczka A., et al. Cowpox virus outbreak in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) with a time-delayed infection to humans. PLoS One 2009, 4:e6883. doi:10.1371/journal.pone.0006883.
445. Essbauer S., Pfeffer M., Meyer H. Zoonotic poxviruses. Vet Microbiol 2010, 140:229-236.
446. Poland G.A., Neff J.M. Smallpox vaccine: problems and prospects. Immunol Allergy Clin North Am 2003, 23:731-743.
447. World Health Organization Report of the meeting of the Ad Hoc Committee on Orthopoxvuris Infections 1994, World Health Organization, Geneva, Switzerland, September 9.
448. Mahy B.W., Almond J.W., Berns K.I., et al. The remaining stocks of smallpox virus should be destroyed. Science 1993, 262:1223-1224.
449. Roizman B., Joklik W., Fields B., et al. The destruction of smallpox virus stocks in national repositories: a grave mistake and a bad precedent. Infect Agents Dis 1994, 3:215-217.
450. McFadden G. Killing a killer: what next for smallpox?. PLoS Pathog 2010, 6:e1000727. doi:10.1371/journal.ppat.1000727.
451. Tucker J.B. Breaking the deadlock over destruction of the smallpox virus stocks. Biosecur Bioterror 2011, 9:55-67.
452. Smith S.K., Olson V.A., Karem K.L., et al. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother 2009, 53:1007-1012.
453. Damon I.K., Davidson W.B., Hughes C.M., et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009, 90(pt 8):1962-1966.
454. Reeves P.M., Smith S.K., Olson V.A., et al. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J Virol 2011, 85:21-31.
455. Institute of Medicine Live Variola Virus: Considerations for Continuing Research 2009, National Academies Press, Washington DC.
456. Advisory Group of Independent Experts to Review the Smallpox Programme Comments on the Scientific Review of Variola Virus Research, 1999-2010 2010, World Health Organization, Geneva, Switzerland, December.
457. Mckay B. Bioterror fears prompt U.S. to keep its smallpox cache. Wall Street J (East Ed) 2011, January 18.
458. Poland G.A., Henderson D. Thirty years after smallpox: celebration and sobering thoughts. Vaccine 2010, 28:4013-4014.
459. Sixty-fourth World Health Assembly closes after passing multiple resolutions. World Health Organization Web site. Accessed January 3, 2012. http://www.who.int/mediacentre/news/releases/2011/world_health_assembly_20110524/en/index.html.
460. Poland G.A., Lane J.M. Why not destroy the remaining smallpox virus stocks?. Vaccine 2011, 29:2823-2824.
461. Henderson D.A. Smallpox virus destruction and the implications of a new vaccine. Biosecur Bioterror 2011, 9:163-168.